Activity of oral atovaquone alone and in combination with antimony in experimental visceral Leishmaniasis Academic Article uri icon

Overview

MeSH Major

  • Antimony
  • Antiprotozoal Agents
  • Leishmania donovani
  • Leishmaniasis, Visceral
  • Naphthoquinones

abstract

  • BALB/c mice with established visceral infection caused by the intracellular protozoan Leishmania donovani were treated with oral atovaquone for 7 days. Treatment with 100 mg/kg of body weight per day was optimal and halted parasite replication in the liver. In mice treated with atovaquone, the effect of a suboptimal dose of pentavalent antimony was converted from partially leishmanistatic to leishmanicidal. These results demonstrate the in vivo antileishmanial effect of atovaquone and suggest a potential role for this oral agent in visceral leishmaniasis as an adjunct to conventional antimony treatment.

publication date

  • March 1996

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC163162

PubMed ID

  • 8851575

Additional Document Info

start page

  • 586

end page

  • 7

volume

  • 40

number

  • 3